GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                                                                Synonyms: compound B [WO2022002018A1] | LY-3499446
                                 Compound class: 
                                                            Synthetic organic
                                 
                                    
                                        Comment: LY3499446 is a direct inhibitor of oncogenic KRAS mutant G12C that was developed for anticancer potential [1].
                                    
                                 | 
 | |||||||||||||||||||||||||||||||||||
| References | 
| 1. Uprety D, Adjei AA. (2020) KRAS: From undruggable to a druggable Cancer Target. Cancer Treat Rev, 89: 102070. [PMID:32711246] | 
| 2. Yu S, Li B. (2022) Compound for inhibiting krasg12c mutant protein, preparation method therefor, and use thereof. Patent number: WO2022002018A1. Assignee: Suzhou Wentian Pharmaceutical Technology Co. Priority date: 03/07/2020. Publication date: 06/01/2022. |